학술논문
A randomized, double-blind trial evaluating the efficacy and safety of monotherapy with the once-weekly dipeptidyl peptidase-4 inhibitor omarigliptin in people with type 2 diabetes
Document Type
Article
Author
Source
In Diabetes Research and Clinical Practice April 2018 138:253-261
Subject
Language
ISSN
0168-8227